



1619

PATENT CASE CV01489K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Harry R. Davis et al.

For:
**COMBINATIONS OF PEROXISOME
PROLIFERATOR-ACTIVATED RECEPTOR
(PPAR) ACTIVATOR(S) AND STEROL
ABSORPTION INHIBITOR(S) AND
TREATMENTS FOR VASCULAR
INDICATIONS**

Serial No.: 10/057,323

Filed: January 25, 2002

Assistant Commissioner of Patents
Washington, D.C. 20231

Examiner: To Be Assigned
Group Art Unit: 1619
Attorney Docket No.: CV01489K

RECEIVED
APR 08 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the documents listed on the accompanying PTO Form 1449 be considered and made of record in the above-identified patent application. A copy of each cited document is attached.

The Commissioner is authorized to charge Deposit Account No. 19-0365 for any additional fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.


Respectfully submitted,

Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, New Jersey
7033-530

Ann Marie Cannon
Ann Marie Cannon
Reg. No. 35,972
Attorney for Applicants
(908) 298-5024

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON D.C. 20231 ON 3/21/03 ANN MARIE CANNON, REG. NO. 35,972
(DATE OF DEPOSIT) (REGISTERED REPRESENTATIVE)

Ann Marie Cannon 3/21/03
(SIGNATURE AND DATE)



Sheet 1 of 8

FORM PTO-144 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057,323
				APPLICANT: Harry R. Davis et al.	
				FILING DATE: January 25, 2002	GROUP: 1619

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
FQ	WO 97/21676	06/19/97	PCT	C07D	205/09	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FR	WO 97/41098	11/06/97	PCT	C07D	205/09	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FS	WO 00/23415	04/27/00	PCT	C07C	69/734	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FT	WO 00/23416	04/27/00	PCT	C07C	69/734	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FU	WO 00/23425	04/27/00	PCT	C07D	209/80	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FV	WO 00/23445	04/27/00	PCT	C07D	471/12	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FW	WO 00/23451	04/27/00	PCT	C07D	487/14	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FX	WO 00/28981	05/25/00	PCT	A61K	31/00	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FY	WO 00/31548	06/02/00	PCT	G01N	33/68	<input checked="" type="checkbox"/> RECEIVED APR 01 2003
FZ	WO 00/32189	06/08/00	PCT	A61K	31/415	
GA	WO 00/34240	06/15/00	PCT	C07D	205/08	
GB	WO 00/37057	06/29/00	PCT	A61K	9/48	
GC	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)
GD	WO 00/38721	07/06/00	PCT	A61K	45/06	
GE	WO 00/38722	07/06/00	PCT	A61K	45/06	
GF	WO 00/38723	07/06/00	PCT	A61K	45/06	
GG	WO 00/38724	07/06/00	PCT	A61K	45/06	
GH	WO 00/38725	07/06/00	PCT	A61K	45/06	
GI	WO 00/38726	07/06/00	PCT	A61K	45/06	
GJ	WO 00/38727	07/06/00	PCT	A61K	45/06	
GK	WO 00/38728	07/06/00	PCT	A61K	45/06	
GL	WO 00/38729	07/06/00	PCT	A61K	45/06	
GM	WO 00/40247	07/13/00	PCT	C07D	265/26	
GN	WO 00/45817	08/10/00	PCT	A61K	31/505	
GO	WO 00/50392	08/31/00	PCT	C07C	323/52	X(abs.)
GP	WO 00/53149	09/14/00	PCT	A61K		
GQ	WO 00/53173	09/14/00	PCT	A61K	31/22	
GR	WO 00/53563	09/14/00	PCT	C07C	59/92	X(abs.)
GS	WO 00/56403	09/28/00	PCT	A61P	9/10	
GT	WO 00/57859	10/05/00	PCT	A61K	9/48	
GU	WO 00/57918	10/05/00	PCT	A61K	47/44	
GV	WO 00/60107	10/12/00	PCT	C12P	17/10	
GW	WO 00/63153	10/26/00	PCT	C07C	69/734	
GX	WO 00/63161	10/26/00	PCT	C07C	237/30	
GY	WO 00/63190	10/26/00	PCT	C07D	265/38	
GZ	WO 00/63196	10/26/00	PCT	C07D	277/04	
HA	WO 00/63209	10/26/00	PCT	C07D	471/04	
HB	WO 00/63703	10/26/00	PCT	G01N	33/92	
HC	WO 00/69412	11/23/00	PCT	A61K	9/127	
HD	WO 00/69445	11/23/00	PCT	A61K	31/785	
HE	WO 00/72825	12/7/00	PCT	A61K	9/14	
HF	WO 00/72829	12/07/00	PCT	A61K	9/48	

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

P ATENT & TRADEMARK OFFICE	S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.:	SERIAL NO.:	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				CV01489K	10/057,323	
					APPLICANT:	Harry R. Davis et al.	
					FILING DATE:	GROUP:	
					January 25, 2002	1619	
HG	WO 00/75103	12/14/00	PCT	C07C	235/60	X(abs.)	
HH	WO 00/76482	12/21/00	PCT	A61K	9/48		
HI	WO 00/76488	12/21/00	PCT	A61K	31/00		
HJ	WO 00/78312	12/28/00	PCT	A61K	31/421		
HK	WO 00/78313	12/28/00	PCT	A61K	31/422		
HL	WO 01/00579	01/04/01	PCT	C07D	213/65		
HM	WO 01/00603	01/04/01	PCT	C07D	277/24		
HN	WO 01/08686	02/08/01	PCT	A61K	31/495		
HO	WO 01/12176	02/22/01	PCT	A61K	31/16		
HP	WO 01/12187	02/22/01	PCT	A61K	31/404		
HQ	WO 01/12612	02/22/01	PCT	C07D	257/04		
HR	WO 01/14349	03/01/01	PCT	C07D	277/34	X(abs.)	
HS	WO 01/14350	03/01/01	PCT	C07D	277/34	X(abs.)	
HT	WO 01/14351	03/01/01	PCT	C07D	277/34	X(abs.)	
HU	WO 01/15744	03/08/01	PCT	A61K	49/00		
HV	WO 01/16120	03/08/01	PCT	C07D	263/32		
HW	WO 01/17994	03/15/01	PCT	C07D	413/12		
HX	WO 01/18210	03/15/01	PCT	C12N	15/12		
HY	WO 01/21181	03/29/01	PCT	A61K	31/675	X(abs.)	
HZ	WO 01/21259	03/29/01	PCT	A61P			
IA	WO 01/21578	03/29/01	PCT	C07C	235/60	X(abs.)	
IB	WO 01/21647	03/29/01	PCT	C07K	14/00		
IC	WO 01/22962	04/05/01	PCT	A61K	31/435		
ID	WO 01/25225	04/12/01	PCT	C07D	317/18		
IE	WO 01/25226	04/12/01	PCT	C07D	327/04		
IF	WO 01/30343	05/03/01	PCT	A61K	31/40		
IG	WO 01/32161	05/10/01	PCT	A61K	31/00		
IH	WO 01/35970	05/25/01	PCT	A61K	35/76		
II	WO 01/40192	06/07/01	PCT	C07D	217/26	X(abs.)	
IJ	WO 01/45676	06/28/01	PCT	A61K	9/24		
IK	WO 01/49267	07/12/01	PCT	A61K	9/14		
IL	WO 01/64221	09/07/01	PCT	A61K	31/52		
IM	WO 01/76632	10/18/01	PCT	A61K	45/06		
IN	WO 02/50090	06/27/02	PCT	C07H	15/26		
IO	WO 02/058696	08/01/02	PCT	A61K	31/397		
IP	WO 02/058731	08/01/02	PCT	A61K	45/06		
IQ	WO 02/058732	08/01/02	PCT	A61K	45/06		
IR	WO 02/058733	08/01/02	PCT	A61K	45/06		
IS	WO 02/058734	08/01/02	PCT	A61K	45/06		
IT	WO 02/058685	08/01/02	PCT	A61K	45/06		
IU	WO 02/064130	08/22/02	PCT	A61K	31/00		
IV	WO 02/064549	08/22/02	PCT	A61K	31/195		
IW	WO 02/064664	08/22/02	PCT	C07C	275/34		
IX	WO 02/072104	09/19/02	PCT	C08G	77/02		
IY	WO 02/081454	10/17/02	PCT	A61K	31/54		
IZ	WO 02/26729	04/04/02	PCT	C07D	239/36		
JA	WO 02/064094	08/22/02	PCT	C07D	311/66		
				A61K			

RECEIVED



Sheet 3 of 8

APR 01 2003

RECEIVED
TECH CENTER 1600/2000

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.: CV01489K
SERIAL NO.: 10/057,323
APPLICANT:
Harry R. Davis et al.
FILING DATE: APR 01 2003
GROUP: 100/2000

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
•	JB	Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic & Medicinal Chemistry Ltrs.</i> , Oxford, G.B., 8:313-318 (1998)
	JC	Vaccaro, W.D. et. al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Bioorganic & Medicinal Chem. Ltrs. Oxford</i> , G.B. 8:319-322 (1998)
•	JD	H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)
	JE	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", <i>Chemical Abstracts No.</i> 15, 86 (April 11, 1997)
	JF	Otto et al., "Stereochemistry of dehydration and halogenation of α R* and α S* isomeric 3-(α -hydroxybenzyl)-1,4-diphenyl-2-azetidinones", <i>Chemical Abstracts No.</i> 19, 99 (Nov. 7, 1983)
•	JG	T. Durst et al, "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" <i>Canadian Journal of Chemistry</i> , 50:3196-3201 (1971)
	JH	Nobuki, O. et al., "Stereoselective syntheses of β -lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No.</i> 106, 17 (April 27, 1987)
•	JI	M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", <i>J. Agric. Food Chem.</i> , 30:920-024 (1982)
•	JJ	H. Otto et al. "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)
•	JK	G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrate and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)
•	JL	Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", <i>26 Tetrahedron Letters</i> , 45:5493-5496 (1985)
•	JM	Panfil, I. et al. "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" <i>24 Heterocycles</i> 6:1609-1617 (1986)
•	JN	D. Roger Illingworth, "An Overview of Lipid-Lowering Drugs" <i>Drugs</i> 36:63:71 (1988)
•	JO	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)
•	JP	B. Ram et al. "Potential Hypolipidemic agents: Part V", 29B <i>Indian J. Chem.</i> 1134-37 (1990)
•	JQ	Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA: Choleseraol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)
•	JR	Horie, M. et al, "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)
•	JS	Baxter, A., "Squalenestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)
•	JT	Summary Factfile, "Anti-Atherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)
•	JU	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" <i>Journal of Lipid Research</i> 34:377-395 (1993)
•	JV	Salisbury, B. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115:45-63 (1995)



Sheet 4 of 8

RECEIVED
TECH CENTER 1600/2000
APR 03 2003
1600/2000

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057,327
			APPLICANT: Harry R. Davis et al.	
			FILING DATE: January 25, 2002	GROUP: 1619
✓	JW	Clader, J. W. et al., "Substituted (1,2-Diarylethyl)amide Acyl-CoA;Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38:1600-1607 (1995)		
✓	JX	Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)		
✓	JY	Vaccaro, W, et al, "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. & Med. Chem.</i> 6:1429-1437 (1998)		
✓	JZ	G. Wu et al, "A Novel One-Step Diastereo-and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).		
✓	KA	B. Staels, "New Roles for PPARS in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22:9 p. 444 (Sept. 2001)		
✓	KB	Abbott et al, "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.		
✓	KC	M. Feher et al., 1991, <i>Lipids and Lipid Disorders</i> , p.1-87 (1991).		
✓	KD	M. Ricote et al., "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22, No. 9 44-443 (2001)		
✓	KE	C. Dujovne et al, "Reduction of LDL Cholesteral in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a mutlicenter Dose-Ranging Study", <i>J. Clin., Pharm.</i> 41:1 70-78 (Jan. 2001)		
✓	KF	W. Oppolzer et al., "Asymmetric Diels – Alder Reactions, Facile Preparation and Structure of Sulfonamido – Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25:5885-5888 (1984).		
✓	KG	M. Davidson et al., "Colesevvelam Hydischloride: a non-absorbed, polymeric cholesterol lowing agent", <i>Expert Opinion Investigating Drugs</i> , 11:2663-71, (Nov. 2000)		
✓	KH	M. Davidson et al., "Colesevvelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", 159 <i>Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)		
✓	KI	I. Wester, "Cholesterol – Lowering effect of plant sterols", <i>Euro. J.Lipid, Sci. Tech.</i> 37-44 (2000).		
✓	KJ	A. Andersson et al., "Cholesterol –lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowing diet", 1 <i>European Heart. J. Supplements</i> S80 - S90 (1999)		
✓	KK	H. Gylling et al, "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostarol Ester Margarine, 96 <i>Circulation</i> 12 4226-4231 (Dec. 16, 1997)		
✓	KL	T. Miettinen et al, "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)		
✓	KM	T. Bocan et al., "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)		
✓	KN	M. Van Heek et al., "In Vivo Metabolism – Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," 283 <i>J. Pharma and Experimental Therapeutics</i> 1 157-163 (1997)		
✓	KO	H. Davis et al., "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," 151 <i>Atherosclerosis</i> 1:133 (July 2000)		

O I P E
APR 01 2003
JC176

Sheet 5

TECH CNT
APR 8
2003

RECEIVED
APR 8
2003
USPTO
2002/2003

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057-323 2003
			APPLICANT: Harry R. Davis et al.	
			FILING DATE: January 25, 2002	GROUP 1619
	KP	L. Nguyen et al., "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", <i>10 Atherosclerosis</i> 2, 289-297 (1990)		
	KQ	L. Nguyen et al., "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," <i>32 J.Lipid Res.</i> 1941-1948 (1991)		
	KR	M. Cobb et al., "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," <i>45 Metabolism</i> 6 673-679 (June 1996)		
	KS	M. Huettlinger et al., "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", <i>13 Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).		
	KT	J. Best et al., "Diabetic Dyslipidaemia", <i>59 Drugs</i> 5 1101-1111 (May 2000)		
	KU	P. Chong, et al, "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", <i>60 Drugs</i> 1 55-93 (July 2000)		
	KV	M. Brown et al, "A Receptor – Mediated Pathway for Cholesterol Homeostasis", <i>232 Science</i> 34-47 (April 4, 1986)		
	KW	L. Lipka et al., "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)		
	KX	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 th Ed. 2001)		
	KY	K. Fassbender et al., "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides $\text{A}\beta$ 42 and $\text{A}\beta$ 40 in vitro and in vivo", <i>PNAs Early Edition</i> , www.pnas.org/cgi/doi/10.1073/pnas.081620098 (2001)		
	KZ	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)		
	LA	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001		
	LB	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001		
	LC	Dementia and Statins", <i>The Lancet</i> March 17, 2001		
	LD	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001		
	LE	Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com April 10, 2001		
	LF	Lovastation XL of Use in Alzheimer's? News Edge (May 2, 2001)		
	LG	L. Refolo et al, "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Morse Model, <i>Neurobiology of Disease</i> 321-331 (2000)		
	LH	D. Kang et al., "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor – Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)		
	LI	Y.A. Kesaniewmi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)		
	LJ	J. Busciglio et al., "Generation of β -amyloid in the secretary pathway in neuronal and nonneuronal cells", <i>90 Proc. Nat'l. Acad. Sci. USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)		
	LK	L. Farrer et al., "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)		
	LL	A. Goate et al., "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", <i>349 Nature</i> No. 6311, 704-706 (Feb. 21, 1991)		

APR 01 2003

Sheet

6

8

TECH

RECEIVED
MAY 8 2003
160012000

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/051823
			APPLICANT: Harry R. Davis et al.	
			FILING DATE: January 25, 2002	GROUP: 1619
·	LM	D: Mann et al., "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", 89 <i>J. Neuro. Sci.</i> , 169-179 (Feb. 1989)		
·	LN	G. McKhann et al., "Clinical Diagnosis of Alzheimer's Disease", 34 <i>Neurology</i> No. 7, 939-944 (July 1984)		
·	LO	D. Selokoe, "Alzheimer's Disease: Genotypes, Pheontype and Treatments", 275 <i>Science</i> , 630-631 (Jan. 31, 1997)		
·	LP	C. Van Duijn, et al., "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", 20 <i>Int'l J. Epidemiology</i> No. 2 (Suppl. 2), 513-520 (1991)		
·	LQ	T Nagahara et al., "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem.</i> 37:1200-1207 (1994)		
·	LR	Mellott et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistasin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)		
·	LS	Sitko et al., "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:808-815 (1992)		
·	LT	Seymour et al., 1994, <i>Biochemistry</i> , 33:3949-3959		
·	LU	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479		
·	LV	Mendall et al., "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> , 312:1061-1065 (April 27, 1996)		
·	LW	Ridker P. et al., "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", 46 <i>J. Investig. Med.</i> ; 8:391-395 (1998)		
·	LY	Waters, D. et al., "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> ; 82:1940-1953 (1990)		
·	LZ	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 13-16		
·	MA	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley</i> , New York, pp. 286-313		
·	MB	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11		
·	MC	Remington 1995, "The Science and Practice of Pharmacy, (19 th Ed. 1995) p. 963		
·	MD	M. Chistie et al., "Early - Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", 276 <i>J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)		
·	ME	C. Janus et al., "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", 408 <i>Nature</i> 21/28; 979-982 (Dec. 2000)		
·	MF	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)		
·	MG	Steiner, PM et al., "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract]", <i>J. Clin. Chem. Clin. Biochem.</i> 19:850 (1981)		
·	MH	Steele WG, et al., "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, 22 <i>Clin. Chem.</i> ; 1:98-101 (1976)		
·	MI	Salen et al., "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Cholesterol Syntheses in Sitosterolemia with Xanthomatosis", <i>J. Lipd Res.</i> ,; 30:1319-1330 (1989)		



Sheet 7

APR 8

TECH-03
160012900

RECEIVED

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.: CV01489K
SERIAL NO.: 10/057,023

APPLICANT:
Harry R. Davis et al.

FILING DATE:
January 25, 2002
GROUP:
1619

	MJ	Lutjohann et al., "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", <i>J. Lipid Res.</i> , 36 :8; 1763-1773 (1995)
	MK	Zhang et al., "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of γ - Secretase" 274 <i>J. Biol. Chem.</i> , 13:8966-8972 (1999)
	ML	Zhang et al., "Biochemical Characterization of the γ -Secretase Activity that Produces B-Amyloid Peptides", <i>Biochemistry</i> 40 :5049-5055 (2001)
	MM	Ida et al., "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", 271 <i>J. Biol. Chem.</i> ; 37:22908-22914 (1996)
	MN	Lichtlen, P.R. et al., 1990, <i>Lancet</i> , 335 :1109-1113
	MO	Bays et al., "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", <i>Clinical Therapeutics</i> , 23 :1209-1230 (2001)
	MP	E. Leitersdorf et al., "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", <i>European Heart Journal Supplement</i> , 3 :E17-E23 (June 2001)
	MQ	Bauer et al., "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", <i>Clinical Pharmacology and Therapeutics</i> , 69 :2 p5 (Mar. 6-10, 2001)
	MR	Keung et al., "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives", <i>Clinical Pharmacology and Therapeutics</i> , 69 :2 p55 (Mar. 6-10, 2001)
	MS	Kosoglou et al., "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs 72nd EAS Congress</i> , p. 38 (May 21-23, 2001)
	MT	T. Kosoglou et al., "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", <i>Posters 11. Lipid Lowering Drugs/Novel</i> , 72nd EAS Congress , p. 89 (May 21-23, 2001)
	MU	L. Reyderman et al., "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)
	MV	P. Statkevich et al., "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", <i>Clinical Pharmacology & Therapeutics</i> , 69 :67 (March 6-10, 2001)
	MW	Knopp et al, "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", <i>Posters 11. Lipid Lowering Drug/Novel 72nd EAS Congress</i> , p. 90 (May 21-23, 2001)
	MX	Kosoglou et al., "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs, 72nd EAS Congress</i> , p. 38 (March 6-10, 2001)
	MY	Bays et al., "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden</i> (June 25-29, 2000)
	MZ	Castaner et al, "Ezetimibe – Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , 25 (7):679-685 (2000)
	NA	Lipka et al., "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA</i> (March 12-15, 2000)
	NB	Van Heek et al., "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor , SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , 129 :1748-1754 (2000)



APR 01 2003

Sheet 8 of 8

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO.: CV01489K SERIAL NO.: 10/057,323 APR 08 2003 TECH CENTER 16002 APPLICANT: Harry R. Davis FILING DATE: January 25, 2002 GROUP: 1619
	NC	Van Heek <i>et al.</i> , 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden (June 25-29, 2000)</i>	
u	ND	Iannucci <i>et al.</i> , "Metabolism of SCH 58235 in the Human, Rat and Dog", <i>47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX (June 13-17, 1999)</i>	
	NE	Reiss <i>et al.</i> , "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic & Medicinal Chemistry</i> , 7 :2199-2202 (1999)	
	NF	Rosenblum <i>et al.</i> , "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41 :973-980 (1998)	
	NG	Vaccaro <i>et al.</i> , "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8 :313-318 (1998)	
u	NH	Zaks <i>et al.</i> , "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73 :205-214 (1998)	
	NI	W. Insull <i>et al.</i> , "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters", <i>World Heart Federation 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke – Abstract Book</i> , p. 35 (June 12-15, 2002)	
u	NJ	L. Simons <i>et al.</i> , 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 th Annual Meeting of the EASD, September 1-5, 2002	
	NK	C. Allain <i>et al.</i> , 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20 :470-475	
	NL	R. Mayrhofer <i>et al.</i> , 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248	
	NM	Burrier, R.E. <i>et al.</i> , 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47 :1545-1551	
	NN	Burrier, R.E. <i>et al.</i> , 1994, "The Effect of Acyl CoACholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272 :156-163	
	NO	E.F. Binder <i>et al.</i> , "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9 :754-760 (May 1, 2001)	
u	NP	MR Haymart <i>et al.</i> , "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gend. Specif. Med.</i> 6 :37-42 (Nov. – Dec. 1997)	
u	NQ	"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)	
	NR	"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)", "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)	
	NS	Van Heek <i>et al.</i> , "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)	
	NT	"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)	
	NU	H. Hauser, <i>et al.</i> , "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37 :17843-17850, 1998	
	NV	G. Salen, <i>et al.</i> , "Sitosterolemia", <i>Journal of Lipid Research</i> 33 :945-955, 1992	
	NW	Stedman's Medical Dictionary, 27 th Edition, pg. 1381	
			DATE CONSIDERED

RECEIVED